Table 1.
Summary of Kaplan-Meier estimates for 2-year OS and 2-year EFS for clinically high-risk patients using each of the 18 proposed models
| LPS | non-LPS | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Outcome | Prob | SE | N | Prob | SE | N | Data | Model | P-value |
| OS | 0.57 | 0.09 | 31 | 0.79 | 0.05 | 59 | Null model | 0.574 | |
| OS | 0.60 | 0.07 | 57 | 0.91 | 0.05 | 33 | G | 1 | 0.081 |
| OS | 0.60 | 0.06 | 60 | 0.93 | 0.05 | 30 | G | 2 | 0.082 |
| OS | 0.55 | 0.09 | 29 | 0.79 | 0.05 | 61 | G | 3 | 0.166 |
| OS | 0.50 | 0.10 | 24 | 0.79 | 0.05 | 66 | G | 4 | 0.164 |
| OS | 0.57 | 0.07 | 55 | 0.94 | 0.04 | 35 | T | 1 | 0.128 |
| OS | 0.56 | 0.07 | 47 | 0.88 | 0.05 | 43 | T | 2 | 0.002 |
| OS | 0.41 | 0.12 | 17 | 0.78 | 0.05 | 73 | T | 3 | 0.048 |
| OS | 0.57 | 0.09 | 33 | 0.79 | 0.05 | 57 | T | 4 | 0.081 |
| OS | 0.61 | 0.07 | 56 | 0.88 | 0.06 | 34 | I | 1 | 0.124 |
| OS | 0.51 | 0.08 | 36 | 0.85 | 0.05 | 54 | I | 2 | 0.027 |
| OS | 0.47 | 0.10 | 25 | 0.81 | 0.05 | 65 | I | 3 | 0.137 |
| OS | 0.43 | 0.10 | 25 | 0.82 | 0.05 | 65 | I | 4 | 0.017 |
| OS | 0.57 | 0.07 | 56 | 0.94 | 0.04 | 34 | TI | 1 | 0.092 |
| OS | 0.54 | 0.07 | 49 | 0.90 | 0.05 | 41 | TI | 2 | 0.001 |
| OS | 0.40 | 0.11 | 21 | 0.81 | 0.05 | 69 | TI | 3 | 0.036 |
| OS | 0.40 | 0.11 | 22 | 0.80 | 0.05 | 68 | TI | 4 | 0.009 |
| OS | 0.42 | 0.10 | 25 | 0.82 | 0.05 | 65 | Ensemble | 0.016 | |
| EFS | 0.39 | 0.08 | 37 | 0.36 | 0.07 | 53 | Null model | 0.616 | |
| EFS | 0.35 | 0.07 | 53 | 0.39 | 0.08 | 37 | G | 1 | 0.299 |
| EFS | 0.34 | 0.07 | 52 | 0.41 | 0.08 | 38 | G | 2 | 0.266 |
| EFS | 0.30 | 0.06 | 58 | 0.50 | 0.09 | 32 | G | 3 | 0.125 |
| EFS | 0.31 | 0.06 | 59 | 0.48 | 0.09 | 31 | G | 4 | 0.125 |
| EFS | 0.29 | 0.06 | 62 | 0.56 | 0.10 | 28 | T | 1 | 0.036 |
| EFS | 0.35 | 0.07 | 51 | 0.40 | 0.08 | 39 | T | 2 | 0.946 |
| EFS | 0.29 | 0.07 | 38 | 0.43 | 0.07 | 52 | T | 3 | 0.065 |
| EFS | 0.31 | 0.07 | 47 | 0.43 | 0.08 | 43 | T | 4 | 0.150 |
| EFS | 0.35 | 0.06 | 66 | 0.43 | 0.10 | 24 | I | 1 | 0.256 |
| EFS | 0.35 | 0.06 | 66 | 0.43 | 0.10 | 24 | I | 2 | 0.256 |
| EFS | 0.29 | 0.07 | 43 | 0.45 | 0.07 | 47 | I | 3 | 0.052 |
| EFS | 0.29 | 0.07 | 42 | 0.44 | 0.07 | 48 | I | 4 | 0.082 |
| EFS | 0.31 | 0.06 | 57 | 0.47 | 0.09 | 33 | TI | 1 | 0.084 |
| EFS | 0.33 | 0.06 | 68 | 0.50 | 0.11 | 22 | TI | 2 | 0.183 |
| EFS | 0.29 | 0.07 | 42 | 0.45 | 0.07 | 48 | TI | 3 | 0.062 |
| EFS | 0.30 | 0.07 | 44 | 0.44 | 0.08 | 46 | TI | 4 | 0.085 |
| EFS | 0.36 | 0.06 | 58 | 0.39 | 0.09 | 32 | Ensemble | 0.599 |
Patients with predicted survival of less than 2 years are labeled as Low Predicted Survival (LPS), and otherwise are non-LPS. Columns labeled “Prob.”, “SE”, and “N” correspond to the estimated probability of 2-year survival, the standard error of the estimate, and the number of patients in the given cohort. The P-values are for the logrank test comparing LPS to non-LPS survival. The “Data” column refers to the type of RNA-seq data used, and the “Model” column refers to the dimension reduction technique used